CytomX Therapeutics (CTMX) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
CytomX Therapeutics (CTMX) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 23.4% versus a loss of 37.2%. Over five years, CTMX leads with a -50.4% price change compared with -79.1% for PHAT. CytomX Therapeutics is the larger company by market cap ($555.6 million vs $550.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | PHAT |
|---|---|---|
| Share price | $2.55 | $6.81 |
| Market cap | $555.64M | $550.94M |
| 1-day change | -0.39% | +0.44% |
| YTD return | -40.14% | -58.95% |
| 1-year return | -23.42% | -37.18% |
| 5-year return | -50.39% | -79.05% |
| Forward P/E | — | 6.33 |
| EPS (TTM) | $-0.51 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.21 | $18.31 |
| 52-week low | $2.48 | $6.52 |
| Distance from 52-week high | -68.94% | -62.81% |
| Average volume | 3.35M | 1.39M |
| Shares outstanding | 217.90M | 80.90M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTMX has outperformed PHAT by 13.8 percentage points over the past year.
CTMX vs PHAT FAQ
Which is bigger, CytomX Therapeutics or Phathom Pharmaceuticals?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $555.64M compared with $550.94M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, CTMX or PHAT?
CTMX returned -23.42% over the past 12 months, compared with -37.18% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.